Quick Answer
Axsome Therapeutics, Inc. reported Revenue (ASC 606) of $638.50 million for fiscal year 2025.
Axsome Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $638.50M | +65.5% |
| 2024 | $385.69M | +42.5% |
| 2023 | $270.60M | +440.8% |
| 2022 | $50.04M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $170.99M | +63.2% | +14.0% |
| June 30, 2025 | $150.04M | +72.1% | +23.5% |
| March 31, 2025 | $121.46M | +62.0% | +15.9% |
| September 30, 2024 | $104.76M | +81.3% | +20.2% |
| June 30, 2024 | $87.17M | +86.7% | +16.2% |
| March 31, 2024 | $75.00M | -20.7% | +29.8% |
| September 30, 2023 | $57.79M | +243.1% | +23.8% |
| June 30, 2023 | $46.70M | +429.5% | -50.6% |
- Axsome Therapeutics, Inc. showed an increase of +65.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2022–2025 period, Axsome Therapeutics, Inc.’s revenue (asc 606) has grown by 1176.0% (from $50.04 million to $638.50 million).
- The most recent figure is from Axsome Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: